Functional Impairment in Children With Externalizing Behavior Disorders: Psychometric Properties of the Weiss Functional Impairment Rating Scale–Parent Report in a German Clinical Sample

Dose, Christina; Hautmann, Christopher; Döepfner, Manfred

doi:10.1177/1087054716661234

Cited by 26 publications

(34 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The domain of Risky Activities has somewhat lower baseline scores than other domains, and taps rare, but salient events that may have high clinical impact even if there are floor effects or lower values than the absolute scores. Some authors (Dose et al 2016 ) have assumed that the domain of Risky Activities is not relevant to a younger population. However, our data demonstrate not only that the domain is relevant, but also that improvement in this domain may have significant impact on the high-risk outcomes of children and adolescents with ADHD.…”

Section: Discussionmentioning

confidence: 99%

“…The WFIRS-P has shown strong psychometric properties in clinical settings (Tarakçıoğlu et al 2015 ), research populations (Gajria et al 2015 ), and population samples (Hadianfard et al 2017 ). Internal consistency was demonstrated by alpha >0.9 for the measure as a whole and >0.7 for all domains (Gajria et al 2015 ); test–retest reliability was evidenced by r > 0.7 after 1–4 weeks; moderate to strong correlations between each domain and the scale as a whole; and confirmatory factor analysis of the domains (Weiss et al 2005 , 2007 ; Molina et al 2009 ; Qian et al 2011 ; Gajria et al 2015 ; Punyapas et al 2015 ; Tarakçıoğlu et al 2015 ; Dose et al 2016 ; Hadianfard et al 2017 ).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial

Weiss

Childress

Mattingly

et al. 2018

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objective: To evaluate the relationship between symptom and functional improvement and remission in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) enrolled in an 11-week open-label dose-optimization phase of an methylphenidate extended release (MPH-MLR) pivotal study.Methods: Assessments included the Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) and ADHD Rating Scale, Fourth Edition (ADHD-RS-IV). Definitions included the following: symptom improvement (≥30% decrease in ADHD-RS-IV total score); symptom remission (ADHD-RS-IV total score ≤18); functional improvement (decrease in WFIRS-P total score ≥0.25 [minimally important difference]); and functional remission (WFIRS-P total score ≤0.65).Results: Two hundred children completed the open-label phase. At initial assessment, functional impairment was evident across all WFIRS-P domains and similar between children and adolescents. Those who were treatment naive had more functional impairment (WFIRS-P total: 0.82 vs. 0.70, p = 0.02). Significant improvements in all WFIRS-P domains were noted at open-label end (p < 0.001), with the largest improvement in Learning. At open-label end, 94% of children and adolescents demonstrated symptom improvement, of which 57% also showed functional improvement, and 75% of children and adolescents showed symptom remission, of which 81% also showed functional remission.Conclusions: Children and adolescents treated with MPH-MLR showed moderate-to-large improvement in functioning during 3 months of treatment, both overall and in specific domains. However, a significant number of those who would be considered symptomatic responders failed to show improvement in functioning or continue to have significant functional impairment. Treatment with MPH-MLR showed that both symptomatic and functional remission are achievable goals. Identification of children and adolescents who have been successfully treated for their symptoms, but continue to suffer functional impairment, will allow us to offer additional targeted treatment interventions over and above medication to address residual difficulties.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial

Weiss

Childress

Mattingly

et al. 2018

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…A domain with at least two items scored ‘2’, one item scored ‘3’, or a mean score above 1.5 may be considered as impaired (CADDRA, ). The subscales as well as the total scale of the original version and German adaptation have satisfactory internal consistency ( α > .70) and factorial validity (CADDRA, ; Dose, Hautmann, & Doepfner, ; Gajria et al., ). In addition, the WFIRS‐P showed test–retest reliability, convergent validity, and responsiveness to change (Gajria et al., ).…”

Section: Methodsmentioning

confidence: 99%

Telephone‐assisted self‐help for parents of children with attention‐deficit/hyperactivity disorder who have residual functional impairment despite methylphenidate treatment: a randomized controlled trial

Dose

Hautmann

Buerger

et al. 2016

Child Psychology Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…A German version of the parent-rated Weiss Functional Impairment Rating Scale, which was modified and adapted for use in preschool-age children, is applied to measure functional impairment [66,67]. The modified German version consists of 40 items, which are rated on a 4-point Likert-type scale ranging from 0 to 3.…”

Section: Clinical Global Impression and Functional Impairmentmentioning

confidence: 99%

“…Higher scores indicate greater impairment. The subscales and total score of the original version and of the modified German version have shown internal consistency (α > .80) and factorial validity [66][67][68]. Moreover, the original version has demonstrated test-retest reliability, convergent validity, and responsiveness to change [68].…”

Section: Clinical Global Impression and Functional Impairmentmentioning

confidence: 99%

Individualised stepwise adaptive treatment for 3–6-year-old preschool children impaired by attention-deficit/hyperactivity disorder (ESCApreschool): study protocol of an adaptive intervention study including two randomised controlled trials within the consortium ESCAlife

Becker

Banaschewski

Brandeis

et al. 2020

Trials

Self Cite

View full text Add to dashboard Cite

Background: Attention-deficit/hyperactivity disorder (ADHD) is a psychosocially impairing and cost-intensive mental disorder, with first symptoms occurring in early childhood. It can usually be diagnosed reliably at preschool age. Early detection of children with ADHD symptoms and an early, age-appropriate treatment are needed in order to reduce symptoms, prevent secondary problems and enable a better school start. Despite existing ADHD treatment research and guideline recommendations for the treatment of ADHD in preschool children, there is still a need to optimise individualised treatment strategies in order to improve outcomes. Therefore, the ESCApreschool study (Evidence-Based, Stepped Care of ADHD in Preschool Children aged 3 years and 0 months to 6 years and 11 months of age (3;0 to 6;11 years) addresses the treatment of 3-6-year-old preschool children with elevated ADHD symptoms within a large multicentre trial. The study aims to investigate the efficacy of an individualised stepwiseintensifying treatment programme. Methods: The target sample size of ESCApreschool is 200 children (boys and girls) aged 3;0 to 6;11 years with an ADHD diagnosis according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) or a diagnosis of oppositional defiant disorder (ODD) plus additional substantial ADHD symptoms. The first step of the adaptive, stepped care design used in ESCApreschool consists of a telephone-assisted self-help (TASH) intervention for parents. Participants are randomised to either the TASH group or a waiting control group. The treatment in step

show abstract

Functional Impairment in Children With Externalizing Behavior Disorders: Psychometric Properties of the Weiss Functional Impairment Rating Scale–Parent Report in a German Clinical Sample

Abstract: The results support the factorial validity, reliability, and divergent validity of the WFIRS-P.

Cited by 26 publications

References 31 publications

Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial

Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial

Telephone‐assisted self‐help for parents of children with attention‐deficit/hyperactivity disorder who have residual functional impairment despite methylphenidate treatment: a randomized controlled trial

Individualised stepwise adaptive treatment for 3–6-year-old preschool children impaired by attention-deficit/hyperactivity disorder (ESCApreschool): study protocol of an adaptive intervention study including two randomised controlled trials within the consortium ESCAlife

Contact Info

Product

Resources

About